Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration
16/11/2023
Pons M, Georgiadis S, Faizy Ahmadzay Z, Østergaard M, Glintborg B, Heberg J, Nysom Christiansen S, Horskjær Rasmussen S, Castrejon I, Alonso F, Laas K, Vorobjov S, Khmelinskii N, Zavada J, Ciurea A, Nissen M, Michelsen B, Mielnik P, Loft A, Rotar Z, Perdan Pirkmajer K, Macfarlane G, Jones G, Nordstrom D, Hokkanen A, van der Horst-Bruinsma I, Karlsson Wallman J, Gudbjornsson B, Palsson o, Hetland M, Ørnbjerg L
ACR 2023
Pons M, Georgiadis S, Faizy Ahmadzay Z, Østergaard M, Glintborg B, Heberg J, Nysom Christiansen S, Horskjær Rasmussen S, Castrejon I, Alonso F, Laas K, Vorobjov S, Khmelinskii N, Zavada J, Ciurea A, Nissen M, Michelsen B, Mielnik P, Loft A, Rotar Z, Perdan Pirkmajer K, Macfarlane G, Jones G, Nordstrom D, Hokkanen A, van der Horst-Bruinsma I, Karlsson Wallman J, Gudbjornsson B, Palsson o, Hetland M, Ørnbjerg L. Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/four-year-secukinumab-treatment-outcomes-in-axial-spondyloarthritis-and-psoriatic-arthritis-patients-treated-in-routine-care-results-from-the-eurospa-collaboration/
https://acrabstracts.org/abstract/four-year-secukinumab-treatment-outcomes-in-axial-spondyloarthritis-and-psoriatic-arthritis-patients-treated-in-routine-care-results-from-the-eurospa-collaboration/